Monday, June 11, 2018

Acute Lymphocytic Leukemia Market Research Report : Ken Research


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Lymphocytic Leukemia - Pipeline Review, H1 2018, provides an overview of the Acute Lymphocytic Leukemia (Oncology) pipeline landscape.
Acute lymphocytic leukemia (ALL) is the cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. It enters the blood stream and rapidly progress to other parts of the body such as spleen, lymph nodes and liver. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain and breathing problems. Treatment includes chemotherapy, transfusions, transplant and medications.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Lymphocytic Leukemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acute Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 3, 58, 52, 2, 69 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 1, 15, 19, 13, 3 and 1 molecules, respectively.
Acute Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Acute Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Lymphocytic Leukemia (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Lymphocytic Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
For more information, click on the link below:
Related Reports:-
https://www.kenresearch.com/healthcare/pharmaceuticals/acute-lymphocytic-leukemia/10084-91.html
https://www.kenresearch.com/healthcare/pharmaceuticals/acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia/31933-91.html
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
sales@kenresearch.com
0124-4230204

Posted by at No comments:
Labels: , ,

Non-Hodgkin Lymphoma market Research Report : Ken Research


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma Market Research Report provides an overview of the Non-Hodgkin Lymphoma (Oncology) pipeline landscape.
Non-Hodgkin lymphoma (also known as non-Hodgkin's lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body's immune system. Symptoms depend on what area of the body is affected by the cancer and how fast the cancer is growing. Symptoms may include night sweats (soaking the bed sheets and pajamas even though the room temperature is not too hot),fever and chills that come and go, itching, swollen lymph nodes in the neck, underarms, groin, or other areas, weight loss, coughing or shortness of breath if the cancer affects the thymus gland or lymph nodes in the chest, putting pressure on the windpipe (trachea) or other airway, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if the cancer affects the brain. Treatment includes surgery, radiation therapy and chemotherapy.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma (Oncology)
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Non-Hodgkin Lymphoma (Oncology) pipeline guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 4, 30, 160, 136, 1, 5, 126, 15 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 19, 22, 17 and 4 molecules, respectively.
Non-Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
 The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non-Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non-Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology)
 Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non-Hodgkin Lymphoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
For more information, click on the link below:
Related Reports:-
https://www.kenresearch.com/healthcare/pharmaceuticals/b-cell-non-hodgkin-lymphoma/42697-91.html
https://www.kenresearch.com/healthcare/pharmaceuticals/frontier-pharma-innovative-licensing-opportunitiesnon-hodgkin-lymphoma/8446-91.html
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
sales@kenresearch.com
0124-4230204


Posted by at No comments:
Labels: , ,

Friday, June 8, 2018

Global T lymphocyte Activation Antigen CD80 Market Outlook 2018: Ken Research

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Cluster of differentiation 80 or CD80 or B7-1 is a protein found on dendritic cells, activated B cells and monocytes. The activated protein induces T-cell proliferation and cytokine production. T-cell proliferation and cytokine production is induced by the binding of CD28.

T lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 2, 4 and 2 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Musculoskeletal Disorders, Dermatology, Genito Urinary System And Sex Hormones, Metabolic Disorders, Ophthalmology and Respiratory which include indications Rheumatoid Arthritis, Autoimmune Disorders, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alopecia, Breast Cancer, Dermatomyositis, Diffuse Large B-Cell Lymphoma, Focal Segmental Glomerulosclerosis (FSGS), Graft Versus Host Disease (GVHD), Granulomatosis with Polyangiitis (Wegener Polyangiitis), Hepatocellular Carcinoma, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Juvenile Rheumatoid Arthritis, Lupus Nephritis, Myasthenia Gravis, Nephrotic Syndrome, Polyarticular Juvenile Idiopathic Arthritis (PJIA), Polymyositis/Idiopathic Inflammatory Myopathy, Renal Cell Carcinoma, Sicca Syndrome (Sjogren), Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Transplant Rejection, Type 1 Diabetes (Juvenile Diabetes), Uveitis and Vitiligo.

The latest report T Lymphocyte Activation Antigen CD80 - Pipeline Review, H1 2018, outlays comprehensive information on the T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
The report provides a snapshot of the global therapeutic landscape for T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80)

The report reviews T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics and enlists all their major and minor projects

The report assesses T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics

To know more, click on the link below:
https://www.kenresearch.com/healthcare/pharmaceuticals/t-lymphocyte-activation-antigen-cd80-pipeline-review-h1-2018/149573-91.html

Related Reports:
https://www.kenresearch.com/healthcare/pharmaceuticals/lymphocyte-activation-gene-3-protein-protein-fdc-or-cd223-or-lag3-pipeline-review-h1/149137-91.html

https://www.kenresearch.com/healthcare/pharmaceuticals/lymphocyte-activation-gene-3-protein-protein-fdc-cd223-lag3/112010-91.html

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
sales@kenresearch.com
0124-4230204
Posted by at No comments:
Labels: , ,

Global Water Sports Equipment Is Expected To Reach USD 18.7 Billion by 2022: Ken Research

Artificial indoor water sporting facilities are expected to gain increased popularity in the global water sports equipment market especially for kayaking and rafting. Owing To Technological Advancements, Changes in Manufacturing Processes, Growth Of Water Sports Infrastructure In Various Regions, Increasing Number Of Sports Championships Organized And Development Of Artificial Water Bodies.
New water sports activities like flyboarding, blob jumping and various others are expected to gain popularity and drive the market further in the coming years.
Jet Skiing has acquired the highest growth in terms of CAGR of consumer expenditure incurred on its equipments. This was close to 10% during 2012-2017. The market has been anticipated to capture highest growth again in the future period registering a CAGR of close to 12%.
Dominance of female participants in water sports is expected to rise in the forecast period. Similarly, participants in the age group of 18-30 years would also show a significantly higher share in 2022.
Although, Americas would remain to be the market leader in terms of consumer expenditure in 2022, its share in the global market would decrease owing to rise in tourism and awareness in APAC and MEA region. 
Analysts at Ken Research in their latest publication “Global Water Sports Equipment Market Outlook to 2022 – By Major Water Sports (Surfing, Scuba Diving, Jet Skiing, Snorkeling, Kiteboarding, Canoeing and Kayaking, Rafting and Parasailing), By Regions (Americas, Europe, APAC and MEA)” believe that promotion of the equipments through training institutions, introduction of free trial and rental facilities offered by the manufacturers and stricter regulations mandating the use of safety equipments will aid the global Water sports equipment market in the forecast period.

Global water sports equipment market is expected to register positive CAGR of close to 7% during the period 2017-2022.
The major factors that may support growth during the forecast period includes rising interest among people for water sports activities, technological advancements carried out by the players in the market, increasing participation rates and changing demographics. In the recent years it has been observed that artificial water bodies for kayaking and rafting are gaining increased popularity among water sports enthusiasts, similar trend would facilitate market size in the future. The U.S. National Whitewater Center situated in Charlotte, North Carolina, US, has the largest artificial river in the world, which is suitable for rafters and kayakers. The technological changes have led to the development of more complex and technical water sports equipment and gear. Moreover, it has paved the way for improvements in many product features. Currently, raw materials are being developed in such a way that it withstands the corrosive ocean atmosphere, which not only increases the longevity of water sports gear and equipment, but also makes these gear and equipment more comfortable to use. More efficient and easy-to-use fins allow divers of all types, from beginners to professionals, to easily navigate underwater. Eventually, these technological improvements in equipment are expected to make it much easier for people to pursue water sports. A rapid growth in the interest for underwater photography is visible among the people in the recent years especially in the regions APAC and MEA. This is a great opportunity for growth in the scuba diving and snorkeling participation rates and related equipment market.
The technological changes have led to the development of more complex and technical water sports equipment and gear. Moreover, it has paved the way for improvements in many product features. Currently, raw materials are being developed in such a way that it withstands the corrosive ocean atmosphere, which not only increases the longevity of water sports gear and equipment, but also makes these gears and equipments more comfortable to use. For instance, rubber and plastics enhance the snug fit of masks and goggles and treated glass improves divers' safety. More efficient and easy-to-use fins allow divers of all types, from beginners to professionals, to easily navigate underwater. Eventually, these technological improvements in equipment are expected to make it much easier for people to pursue water sports. Wide spread awareness among the people regarding the health benefits of the water sports activities such as rafting, scuba diving, snorkeling and others are expected to raise the demand for the equipments among the people. An increased interest among the people towards recreational activities is leading many countries to hold events and championships that shall raise the awareness and participation rates of the sport. In 2018, a surf expo is scheduled to be held in Orlando, Florida, US. More of such similar events are expected to be held in different parts of the world. Such activities shall raise the demand for water sports equipments in the coming years.
Key Topics Covered in the Report:
Global Parasail market
Snorkeling masks market
Surfing participation in US
Telescoping paddle market
Personal Watercraft market
Gear and accessories market
Global Surfboards market
Kiteboarding equipment market
Decompression chamber market
Snorkeling equipment market
Parasailing equipment market
Scuba diving equipment market
Global Water sports equipment market
For more information on the research report, refer to below link:
Related Reports
Contact Us:
Ken Research 
Ankur Gupta, Head Marketing & Communications
+91-9015378249
Posted by at No comments:
Labels: , , , ,

Fanconi Anemia Market Research Report-Ken Research

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fanconi Anemia - Pipeline Review, H1 2018, provides an overview of the Fanconi Anemia (Hematological Disorders) pipeline landscape.
Fanconi anemia (fan-KO-nee uh-NEE-me-uh), or FA, is a rare, inherited blood disorder that leads to bone marrow failure. The disorder also is called Fanconi's anemia. FA is a type of aplastic anemia. In aplastic anemia, the bone marrow stops making or doesn't make enough of all three types of blood cells. Low levels of the three types of blood cells can harm many of the body's organs, tissues, and systems. Treatment is recommended for significant cytopenias, such as hemoglobin less than 8 g/dL, platelets fewer than 500/?L.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fanconi Anemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Fanconi Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Fanconi Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fanconi Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 2 molecules, respectively.
Fanconi Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
 The pipeline guide provides a snapshot of the global therapeutic landscape of Fanconi Anemia (Hematological Disorders).
The pipeline guide reviews pipeline therapeutics for Fanconi Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Fanconi Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Fanconi Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Fanconi Anemia (Hematological Disorders).
 Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Fanconi Anemia (Hematological Disorders).
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding Fanconi Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

For more information on the research report, refer to below link:

Related Reports:

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
Posted by at No comments:
Labels: , , ,
Subscribe to: Comments (Atom)